Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04442737
Other study ID # CR108757
Secondary ID TMC114FD2HTX4004
Status Completed
Phase Phase 4
First received
Last updated
Start date July 1, 2020
Est. completion date August 24, 2023

Study information

Verified date September 2023
Source Janssen Scientific Affairs, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the percent change in body weight when switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) (Immediate Switch Arm) compared to continuing the current integrase (INI) + tenofovir alafenamide/emtricitabine (TAF/FTC) antiretroviral (ARV) regimen (Delayed Switch Arm) in virologically-suppressed human immunodeficiency virus (HIV)-1 infected participants who have experienced rapid and significant body weight gain.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date August 24, 2023
Est. primary completion date August 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Body Mass Index (BMI) of greater than or equal to (>=) 18 kilogram per meter square (kg/m^2) at time of starting an integrase (INI)-based regimen plus Tenofovir Alafenamide/Emtricitabine (TAF/FTC) antiretroviral (ARV) regimen - Documented human immunodeficiency virus (HIV)-1 infection - Currently being treated with a stable ARV regimen consisting of an INI combined with TAF/FTC for >=6 consecutive months preceding the screening visit and experienced a >=10 percent (%) increase in body weight within a 36-month time period prior to screening and while on the current INI + TAF/FTC ARV regimen - Documented evidence of being virologically suppressed while on the current stable INI+TAF/FTC ARV regimen prior to screening - At least one plasma HIV-1 RNA measurement less than (<) 50 copies/milliliter (mL) occurring between 12 and 2 months prior to the screening visit while on the stable INI+ TAF/FTC ARV regimen and have HIV-1 RNA <50 copies/ mL at the screening visit Exclusion Criteria: - Known history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma - Known allergies, hypersensitivity, or intolerance to D/C/F/TAF fixed-dose combination (FDC) tablet or its excipients - Active hepatitis B (HBV) or hepatitis C virus (HCV) infection - Uncontrolled diabetes that will require treatment with insulin during the study period - Evidence of Child Pugh Class C based on clinical laboratory testing and clinical evaluation - History of failure on darunavir (DRV) treatment or known documented history of >=1 DRV resistance-associated mutations (RAM) - Screening hepatic transaminases >5x the upper limit of the normal range - Screening creatinine based estimated glomerular filtration rate (eGFRcr) <30 ml/min according to the Cockcroft-Gault formula for creatinine clearance - Participants initiating or discontinuing concomitant medications associated with significant changes in weight within the last 90 days

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
D/C/F/TAF FDC
A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
TAF/FTC FDC
TAF/FTC ARV regimen will be administered once daily.
INI Based Regimen
The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.

Locations

Country Name City State
United States Atlanta ID Group Atlanta Georgia
United States Medical College of Georgia Augusta Georgia
United States The Office of Franco Felizarta, MD Bakersfield California
United States Care South Clinic Baton Rouge Louisiana
United States Be Well Medical Center, PC Berkley Michigan
United States AIDS Health Foundation-Westside HCC Beverly Hills California
United States University of Alabama at Birmingham Birmingham Alabama
United States Community Research Initiative Boston Massachusetts
United States Montefiore Medical Center Bronx New York
United States The Ruth M. Rothstein CORE Center Chicago Illinois
United States Palmetto Health - USC Columbia South Carolina
United States AIDS Arms Incorporated Trinity Health and Wellness Center Dallas Texas
United States North Texas Infectious Diseases Consultants Dallas Texas
United States Henry Ford Health System Detroit Michigan
United States Midway Immunology and Research Center Fort Pierce Florida
United States Texas Centers for Infectious Disease Associates Fort Worth Texas
United States Therapeutic Concepts - Donald R Watkins Foundation Houston Texas
United States University of Mississippi Medical Center Jackson Mississippi
United States Long Beach Education & Research Consultants Long Beach California
United States DCOL Center for Clinical Research Longview Texas
United States Infectious Disease Associates of Central Virginia Lynchburg Virginia
United States The Corporation of Mercer University Macon Georgia
United States University of Miami Miami Florida
United States Vivent Health Milwaukee Wisconsin
United States AIDS Healthcare Foundation-Research Center New York New York
United States Mount Sinai Hospital-New York New York New York
United States Saint Michaels Medical Center - Infectious Disease Newark New Jersey
United States University of Nebraska Omaha Nebraska
United States Philadelphia Fight Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania
United States Kaiser Permanente Rockville Maryland
United States Washington University School of Medicine Saint Louis Missouri
United States Chatham County Health Department Savannah Georgia
United States Triple O Research Institute West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Janssen Scientific Affairs, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change from Baseline in Body Weight at Week 24 Percent change from baseline in body weight at Week 24 will be reported. Baseline and Week 24
Secondary Change from Baseline in Absolute Body Weight at Weeks 24 and 48 Change from baseline in absolute body weight at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Percentage of Participants with Percent Change in Body Weight Greater Than (>) 3 Percent (%) at Weeks 24 and 48 Percentage of participants with % change in body weight >3% at Weeks 24 and 48 will be reported. Weeks 24 and 48
Secondary Percentage of Participants with Percent Change in Body Weight >5% at Weeks 24 and 48 Percentage of participants with % change in body weight >5% at Weeks 24 and 48 will be reported. Weeks 24 and 48
Secondary Change from Baseline in Body Mass Index (BMI) at Weeks 24 and 48 Change from baseline in BMI at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Body Composition as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan at Weeks 24 and 48 Change from baseline in body composition (absolute mass of fat, lean body mass and total mass) as measured by DEXA scan at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Waist Circumference at Weeks 24 and 48 Change from baseline in waist circumference at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 24 and 48 Change from baseline in SBP and DBP from Baseline at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Fasting Lipids at Weeks 24 and 48 Change from baseline in fasting lipids at Weeks 24 and 48 will be reported. Fasting plasma lipids are measured to determine triglyceride or cholesterol concentrations. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Fasting Glucose at Weeks 24 and 48 Change from baseline in fasting glucose at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Weeks 24 and 48 Change from baseline in HOMA-IR at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Hemoglobin A1c (HbA1c) at Weeks 24 and 48 Change from baseline in HbA1c at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Leptin at Weeks 24 and 48 Change from baseline in leptin at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Adiponectin at Weeks 24 and 48 Change from baseline in adiponectin at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in the Percentage of Participants with Advanced Fibrosis as Assessed by Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score at Weeks 24 and 48 Change from baseline in the percentage of participants with advanced fibrosis according to the NAFLD fibrosis score at Weeks 24 and 48 will be reported. In participants with NAFLD Score less than (< ) -1.455, advanced liver fibrosis can be excluded with high accuracy and NAFLD Score greater than (>) 0.675, the presence of advanced liver fibrosis can be diagnosed with high accuracy. Scores between -1.455 and 0.675 are considered "indeterminate". Baseline, Weeks 24 and 48
Secondary Change from Baseline in the Percentage of Participants at High Risk of Nonalcoholic Fatty Liver Disease (NASH) According to the Hypertension, Age, Insulin, Resistance (HAIR) Score at Weeks 24 and 48 Change from baseline in the percentage of participants at high risk of NASH according to the HAIR score at Weeks 24 and 48 will be reported. HAIR score ranges from 0-3 which is calculated by adding Hypertension = 1, ALT >40 IU=1, and insulin resistance (IR) index >5.0 = 1. A score of greater than or equal to (>=) 2 is high risk for NASH. Baseline, Weeks 24 and 48
Secondary Percentage of Participants with a Dose-reduction or Complete Withdrawal of Anti-hypertensive, Anti-hyperglycemic, or Lipid Lowering Agents Percentage of participants with a dose-reduction or complete withdrawal of anti-hypertensive, anti-hyperglycemic, or lipid lowering agents from baseline to Weeks 24 and 48 will be reported. Baseline up to Weeks 24 and 48
Secondary Percentage of Participants Initiating an Anti-hypertensive, Anti-hyperglycemic, or Lipid Lowering Agent Percentage of participants initiating an anti-hypertensive, anti-hyperglycemic, or lipid lowering agent from baseline to Weeks 24 and 48 will be reported. Baseline up to Weeks 24 and 48
Secondary Percentage of Participants with any Grade Adverse Events (AEs) Percentage of participants with any Grade AEs (related and not related) will be reported. Up to 24 and 48 weeks
Secondary Percentage of Participants with Grade 3 and Grade 4 AEs Percentage of participants with Grade 3 and Grade 4 AEs (related and not related) will be reported where Grade 3: Severe and Grade 4: Potentially life-threatening. Up to 24 and 48 weeks
Secondary Percentage of Participants who Discontinued due to AEs Percentage of participants who discontinued due to AEs will be reported. Up to 24 and 48 weeks
Secondary Percentage of Participants with Serious Adverse Events (SAEs) Percentage of participants with SAEs (related and not related) through Week 24 and Week 48 will be reported. Up to 24 and 48 weeks
Secondary Change from Baseline in Biochemistry Tests Change from baseline in biochemistry tests (such as sodium, potassium, chloride, bicarbonate, blood urea nitrogen, serum creatinine, glucose, aspartate aminotransferase, alanine aminotransferase, insulin, bilirubin [total, direct, indirect], alkaline phosphatase, calcium, calcium corrected for albumin, phosphate, albumin, total protein) through Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Hematology Tests Change from baseline in hematology tests (hematocrit, hemoglobin, platelet count, red blood cell count, absolute neutrophil count, white blood cell count) through Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Urinalysis Tests Change from baseline in urinalysis tests (specific gravity, pH, glucose, protein, blood ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase) through Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Change from Baseline in Urine Chemistry Tests If applicable, change from baseline in urine chemistry tests (urine creatinine, urine sodium, urine phosphate, urine glucose, urine albumin, urine protein, serum creatinine) through Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Percentage of Participants with Grade 3 and Grade 4 Laboratory Abnormalities Percentage of participants with Grade 3 and Grade 4 laboratory abnormalities will be reported. Up to 24 and 48 weeks
Secondary Percentage of Participants with Confirmed Virologic Rebound Percentage of participants with confirmed virologic rebound through Weeks 24 and 48 will be reported. Virologic rebound is defined as the 2 consecutive human immunodeficiency virus type-1 ribonucleic acid (HIV-1 RNA) values greater than or equal to (>=) 200 copies/milliliter (mL) at a scheduled or unscheduled visit after maintaining HIV-1 RNA less than (<) 50 copies/mL. Up to Weeks 24 and 48
Secondary Percentage of Participants with Virologic Response (HIV-1 RNA<50 copies/mL) at Weeks 24 and 48 Percentage of participants with virologic response (HIV-1 RNA <50 copies/mL), at Weeks 24 and 48 according to the Food Drug Administration (FDA) snapshot algorithm will be reported. Weeks 24 and 48
Secondary Percentage of Participants with Virologic Failure (HIV-1 RNA =50 copies/mL) at Weeks 24 and 48 Percentage participants with virologic failure (HIV-1 RNA >=50 copies/mL) at Weeks 24 and 48 according to the FDA snapshot algorithm will be reported. Weeks 24 and 48
Secondary Percentage of Participants Having Virologic Response (HIV-1 RNA<200 copies/mL) at Weeks 24 and 48 Percentage participants with virologic response (HIV-1 RNA < 200 copies/mL) at Weeks 24 and 48 according to the FDA snapshot algorithm will be reported. Weeks 24 and 48
Secondary Percentage of Participants Having Virologic Failure (HIV-1 RNA =200 copies/mL) at Weeks 24 and 48 Percentage participants having virologic failure, that is HIV-1 RNA >= 200 copies/mL, at Weeks 24 and 48 according to the FDA snapshot algorithm will be reported. Weeks 24 and 48
Secondary Change from Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Weeks 24 and 48 Change from baseline in CD4+ cell count at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Percentage of Participants with Pre-baseline Protease (PR), Reverse Transcriptase (RT), and Integrase (INI) Resistance-Associated Mutation (RAMs) Percentage of participants with pre-baseline PR, RT, and INI RAMs based on historical genotypes will be reported. Baseline (Day 1)
Secondary Percentage of Participant with Newly Identified Post-Baseline RAMS and Phenotypic Resistance Compared to Pre-baseline Resistance Tests Percentage of participant with newly identified post-baseline RAMs and phenotypic resistance compared to pre-baseline resistance tests when available, upon meeting confirmed virologic rebound through Week 48. Up to Week 48
Secondary Percentage of Participants with Genotypic and Phenotypic Antiretroviral (ARV) Resistance for Meeting HIV-1 RNA Rebound Criteria up to Weeks 24 and 48 Percentage of participants with genotypic and phenotypic ARV resistance who are meeting HIV-1 RNA rebound criteria through Weeks 24 and 48 will be reported. Up to Weeks 24 and 48
Secondary Change from Baseline in the Percentage of Participants who Have Bothersome Symptoms (Scores of 1, 2, 3 or 4) Across all Items of the HIV-Symptom Index (HIV-SI) at Weeks 24 and 48 Change from baseline in the percentage of participants who have bothersome symptoms (scores of 1, 2, 3 or 4) across all items of the HIV-SI at Weeks 24 and 48 will be reported. The HIV-SI assesses 20 items which are evaluated on a scale of 0-4 where 0= I do not have this symptom to 4=It bothers me a lot'. Minimum HIV-SI score is 0 and maximum HIV-SI score is 80. Baseline, Weeks 24 and 48
Secondary Change from Baseline in the Percentage of Participants who Have Any Symptoms (scores of 1, 2, 3 or 4) Across all Items of the HIV-Symptom Index (HIV-SI) at Weeks 24 and 48 Change from baseline in the percentage of participants who have any symptoms (scores of 1, 2, 3 or 4) across all items of the HIV-SI at Weeks 24 and 48 will be reported. Baseline, Weeks 24 and 48
Secondary Association Between Treatment Arm and Each Bothersome Symptom of the HIV-SI Adjusting for Baseline Variables at Week 24 Association between treatment arm and each bothersome symptom of the HIV-SI adjusting for Baseline variables at Week 24 will be reported. Week 24
Secondary Patient Global Impression of Change (PGIC) Scale The PGIC is a global index that is used to rate the overall status of the participant related to the participant's overall condition. It is rated by the participant and is based on the single question, "compared to before starting the study or compared to the Week 24 and Week 48 visits, my overall status is," where response choices include 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. Weeks 24 and 48
Secondary Adherence Rate to Treatment at Weeks 4, 12 and 24 Adherence rate to treatment will be assessed by participant self-report using 4-day recall at Weeks 4, 12, 24, 36 and 48. Weeks 4, 12, 24, 36 and 48
See also
  Status Clinical Trial Phase
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3
Terminated NCT03708289 - Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals
Completed NCT02547844 - Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla Phase 4
Terminated NCT01345630 - Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 Phase 3
Completed NCT00807443 - Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 Phase 2
Terminated NCT01173276 - Intrauterine Insemination In HIV-Discordant Couples N/A
Completed NCT01140139 - Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions Phase 1
Withdrawn NCT00340223 - HLA-B35 Alleles and AIDS N/A
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT02217904 - A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) Phase 1
Completed NCT00772902 - ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Phase 4
Completed NCT04006704 - Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets Phase 1
Terminated NCT03060629 - A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa Phase 2
Recruiting NCT00981695 - Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers Phase 1/Phase 2
Completed NCT01084343 - Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects Phase 1
Completed NCT00982579 - Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers Phase 1
Completed NCT00665847 - TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents Phase 2
Completed NCT00098293 - Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine Phase 3
Completed NCT05944848 - A Study of CL-197 Capsules in Healthy Participants Phase 1
Completed NCT00479999 - Phase 1 Safety Study of Two Experimental HIV Vaccines Phase 1